Subscribe
SK Life Science’s newly approved treatment for partial-onset seizures is set to launch in the second quarter of 2020, after being designated Schedule V by the DEA.
Antiseizure Medication Tolerability Still a Significant Hurdle
Low-Dose Cannabidiol Effective for Reducing Convulsive Seizures in Dravet Syndrome
Diazepam Nasal Spray Treatment Now Available for Prescription
Fenfluramine NDA Review in Dravet Syndrome Extended 3 Months
Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD
Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA
James F. Howard Jr, MD, FAAN
Basil T. Darras, MD
Karissa Gable, MD
Anne M. Connolly, MD, FAAN; Amy Moore, PhD
Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP